Symptom management and treatments evidence
Access to treatments
Our series of reports on people with MS’ access to treatment, health care services in the UK.
Download our access to treatment reports
MS treatment in England
PDF, 1 MB
MS treatment in Northern Ireland
PDF, 975 KB
MS treatment in Scotland
PDF, 1.1 MB
MS treatment in Wales
PDF, 1.1 MB
Access to treatment and health care - technical report
PDF, 1.4 MB
Dealing with pain and spasticity1 when you have MS is relentless and exhausting - it can make it impossible to manage daily life. Most people with MS will experience these symptoms at some point and, while there are licensed treatments available to help, they don’t work for everyone.
But, we know that cannabinoids (compounds that make up the cannabis plant) could help. In the UK, MS is the only condition which has a licensed treatment derived from cannabis (‘nabiximols’ but also known as Sativex) – used to manage spasticity.
Evidence also increasingly indicates that cannabis itself can be effective in treating pain.
Download our cannabis report
Cannabis and MS report
PDF, 848.6 KB
The project aimed to create a working segmentation of people with MS for the purposes of
developing communications to change their behaviour with respect to disease modifying
DMTs are not a cure for MS, but they can reduce how many relapses someone has and how
serious they are. Currently, 56% of people with MS who could benefit from treatment is
taking one. Evidence also suggests the UK lags behind its European counterparts in access to
Download our Headstrong DMT report
Right treatment right time
Across Scotland more than 11,000 of us live with multiple sclerosis (MS). It can affect the way we think, feel, see and move. It is a lifelong condition with no cure at present, however, over the past 25 years we have seen great strides made in treatments for people living with the relapsing form of the condition.
Access to disease modifying therapies (DMTs) can play an important role in an individual’s MS journey, helping to reduce relapses and slow down the progression of the condition.
Download our right treatment right time report
Time to Act – early treatment
In November 2014, we facilitated a consensus meeting with key members of the MS community to consider the balance of clinical evidence and emerging practice around
whether early treatment with disease modifying therapies (DMTs) improves long-term outcomes for people with MS.
It was attended by people with MS, neurologists, MS nurses, MS Society staff and MS Trust staff. This group of experts agreed that current evidence confirms the importance of treating with DMTs as close as possible to making a diagnosis of MS (consistent with people being able to make informed decisions).
This paper outlines why early treatment is important for people with relapsing forms of MS and what has led to this conclusion.
Download our early treatment report
Time to act - a consensus on early treatment
PDF, 587.2 KB